Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Position Trimmed by OLD National Bancorp IN

OLD National Bancorp IN cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 43,478 shares of the medical research company’s stock after selling 1,243 shares during the quarter. OLD National Bancorp IN’s holdings in Thermo Fisher Scientific were worth $23,078,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of TMO. Savant Capital LLC increased its stake in Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 18 shares during the period. Sugarloaf Wealth Management LLC increased its stake in Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton increased its stake in Thermo Fisher Scientific by 3.7% during the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after buying an additional 19 shares during the period. Tsfg LLC increased its stake in Thermo Fisher Scientific by 8.3% during the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after buying an additional 19 shares during the period. Finally, 1776 Wealth LLC increased its stake in Thermo Fisher Scientific by 2.4% during the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after buying an additional 19 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the completion of the transaction, the chief executive officer now directly owns 43,608 shares in the company, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last ninety days. 0.32% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TMO. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $475.00 to $555.00 in a research note on Wednesday, January 24th. Royal Bank of Canada lifted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, The Goldman Sachs Group lifted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $604.69.

Thermo Fisher Scientific Stock Up 0.6 %

Shares of TMO stock traded up $3.26 during trading on Friday, hitting $544.78. 1,738,509 shares of the company were exchanged, compared to its average volume of 1,199,852. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The firm has a market capitalization of $207.95 billion, a price-to-earnings ratio of 35.26, a P/E/G ratio of 2.29 and a beta of 0.80. The business’s 50-day simple moving average is $571.27 and its 200 day simple moving average is $527.65. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.40 earnings per share. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is 10.10%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.